Cargando…

Structural Basis of Mucopolysaccharidosis Type II and Construction of a Database of Mutant Iduronate 2-Sulfatases

Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is an X-linked genetic disorder caused by a deficiency of iduronate 2-sulfatase (IDS), and missense mutations comprising about 30% of the mutations responsible for MPS II result in heterogeneous phenotypes ranging from the severe to the attenua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saito, Seiji, Ohno, Kazuki, Okuyama, Torayuki, Sakuraba, Hitoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047593/ https://www.ncbi.nlm.nih.gov/pubmed/27695081 http://dx.doi.org/10.1371/journal.pone.0163964

Ejemplares similares

A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation
por: Mashima, Ryuichi, et al.
Publicado: (2023)

Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial
por: Okuyama, Torayuki, et al.
Publicado: (2019)

Shutdown of ER-associated degradation pathway rescues functions of mutant iduronate 2-sulfatase linked to mucopolysaccharidosis type II
por: Osaki, Yosuke, et al.
Publicado: (2018)

Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II
por: Chkioua, Latifa, et al.
Publicado: (2011)

Quantification of the enzyme activities of iduronate-2-sulfatase, N-acetylgalactosamine-6-sulfatase and N-acetylgalactosamine-4-sulfatase using liquid chromatography-tandem mass spectrometry
por: Mashima, Ryuichi, et al.
Publicado: (2017)

The Effect of Recombinant Human Iduronate-2-Sulfatase (Idursulfase) on Growth in Young Patients with Mucopolysaccharidosis Type II
por: Żuber, Zbigniew, et al.
Publicado: (2014)

Frequency of iduronate-2-sulfatase gene variants detected in newborn screening for mucopolysaccharidosis type II in Japan
por: Hattori, Yusuke, et al.
Publicado: (2023)

A cDNA analysis disclosed the discordance of genotype-phenotype correlation in a patient with attenuated MPS II and a 76-base deletion in the gene for iduronate-2-sulfatase
por: Fukuhara, Yasuyuki, et al.
Publicado: (2020)

Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice
por: Morimoto, Hideto, et al.
Publicado: (2022)

Transferrin Receptor-Targeted Iduronate-2-sulfatase Penetrates the Blood-Retinal Barrier and Improves Retinopathy in Mucopolysaccharidosis II Mice
por: Imakiire, Atsushi, et al.
Publicado: (2023)

Changes in Glycogen and Glycosaminoglycan Levels in Hepatocytes of Iduronate-2-Sulfatase Knockout Mice before and after Recombinant Iduronate-2-Sulfatase Supplementation
por: Lee, Jee Hyun, et al.
Publicado: (2011)

Insights into Hunter syndrome from the structure of iduronate-2-sulfatase
por: Demydchuk, Mykhaylo, et al.
Publicado: (2017)

Bioinformatic Analysis of the Human Recombinant Iduronate 2-Sulfate Sulfatase
por: Morales-Álvarez, Edwin D., et al.
Publicado: (2016)

Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II
por: Yamamoto, Ryuji, et al.
Publicado: (2021)

Identification of the iduronate-2-sulfatase proteome in wild-type mouse brain
por: Cardona, Carolina, et al.
Publicado: (2019)

Iduronate-2-sulfatase interactome: validation by yeast two-hybrid assay
por: Benincore-Flórez, Eliana, et al.
Publicado: (2022)

Circadian transcriptome analysis in human fibroblasts from Hunter syndrome and impact of iduronate-2-sulfatase treatment
por: Mazzoccoli, Gianluigi, et al.
Publicado: (2013)

Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome
por: Arguello, Annie, et al.
Publicado: (2021)

Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil
por: Giugliani, Roberto, et al.
Publicado: (2021)

Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II
por: Seo, Joo-Hyun, et al.
Publicado: (2021)

Inhibition of iduronic acid biosynthesis by ebselen reduces glycosaminoglycan accumulation in mucopolysaccharidosis type I fibroblasts
por: Maccarana, Marco, et al.
Publicado: (2021)

Comparative Study of Structural Changes Caused by Different Substitutions at the Same Residue on α-Galactosidase A
por: Saito, Seiji, et al.
Publicado: (2013)

A study of the relationship between clinical phenotypes and plasma iduronate-2-sulfatase enzyme activities in Hunter syndrome patients
por: Lee, Ok Jeong, et al.
Publicado: (2012)

Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Iduronate-2-Sulfatase in Rhesus Macaques
por: Hordeaux, Juliette, et al.
Publicado: (2018)

Comparative studies of vertebrate iduronate 2-sulfatase (IDS) genes and proteins: evolution of A mammalian X-linked gene
por: Holmes, Roger S.
Publicado: (2017)

Iduronate-2-Sulfatase-Regulated Dermatan Sulfate Levels Potentiate the Invasion of Breast Cancer Epithelia through Collagen Matrix
por: Singh, Vishal, et al.
Publicado: (2019)

A boy with mucopolysaccharidosis type II accompanied with a novel variation in heparan-N-sulfatase
por: Li, Yu-Jue, et al.
Publicado: (2019)

The levels of urinary glycosaminoglycans of patients with attenuated and severe type of mucopolysaccharidosis II determined by liquid chromatography-tandem mass spectrometry
por: Mashima, Ryuichi, et al.
Publicado: (2016)

Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease
por: Tsukimura, Takahiro, et al.
Publicado: (2014)

Natural history of cognitive development in neuronopathic mucopolysaccharidosis type II (Hunter syndrome): Contribution of genotype to cognitive developmental course
por: Seo, Joo-Hyun, et al.
Publicado: (2020)

Enhanced osteoblastic differentiation of parietal bone in a novel murine model of mucopolysaccharidosis type II
por: Yamazaki, Narutoshi, et al.
Publicado: (2023)

A novel CRISPR/Cas9-based iduronate-2-sulfatase (IDS) knockout human neuronal cell line reveals earliest pathological changes
por: Badenetti, Lorenzo, et al.
Publicado: (2023)

Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up
por: Furujo, Mahoko, et al.
Publicado: (2017)

Non-invasive intravenous administration of AAV9 transducing iduronate sulfatase leads to global metabolic correction and prevention of neurologic deficits in a mouse model of Hunter syndrome
por: Laoharawee, Kanut, et al.
Publicado: (2023)

Diagnosing Mucopolysaccharidosis type IV a by the fluorometric assay of N-Acetylgalactosamine-6-sulfate sulfatase activity
por: Shams, Sedigheh, et al.
Publicado: (2017)

Biomarkers in patients with mucopolysaccharidosis type II and IV
por: Fujitsuka, Honoka, et al.
Publicado: (2019)

Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification
por: Schlotawa, Lars, et al.
Publicado: (2020)

Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry
por: D’Aco, Kristin, et al.
Publicado: (2012)

Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data
por: Giugliani, Roberto, et al.
Publicado: (2021)

Mucopolysaccharidosis III: Molecular basis and treatment
por: Spahiu, Lidvana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jujeiq5u9ar5s0ie3nvl5kcc2i